Evidence map›Paper›PMID 29428183›Full record

ArticleLancet (London, England)2018

Re-emergence of yaws after single mass azithromycin treatment followed by targeted treatment: a longitudinal study.

Oriol Mitjà, Charmie Godornes, Wendy Houinei, August Kapa, Raymond Paru, Haina Abel, Camila González-Beiras, Sibauk V Bieb, James Wangi, Alyssa E Barry and 3 more

2 registry-linked trialsOpen access · greenAbstract read
In one paragraph

Article in Lancet (London, England), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 47 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
47citing papers in PubMed, 1 pooled it
7.6field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01955252 phase3completednot on this map

Effect of WHO-yaws Elimination Strategy in Lihir Island, Papua New Guinea

TypeinterventionalSponsorLihir Medical CentreRan2013 to 2017Enrolled16,000ConditionsYawsArmsAzithromycin
NCT03490123 phase4completednot on this map

Defining the Best Distribution Strategy of Azithromycin for Yaws Eradication (The Yaws 3 Trial)

TypeinterventionalSponsorLihir Medical CentreRan2018 to 2020Enrolled56,000ConditionsYawsArmsR1-Total community treatment with azithromycin, R2-Total community treatment with azithromycin, R3-Total community treatment with azithromycin, R2-Total targeted treatment with azithromycin, R3-Total targeted treatment with azithromycin
3 · Its place in the literature

Who cites it

47 citing papers in PubMed, 1 synthesis or guideline pooled it, 98 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Article
  4. Article
  5. Observational
  6. Article
  7. Article
  8. Article
  9. Yaws in Africa: Past, Present and Future.Diseases (Basel, Switzerland) · 2025
    Review
  10. Article
  11. Infections caused byClinical microbiology reviews · 2024
    Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. LAMP4yaws:BMJ open · 2022
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

13 authors at 7 institutions in 6 countries.

Oriol MitjàBarcelona Institute for Global Health, Hospital Clinic-University of Barcelona, Barcelona, Spain; Division of Public Health, School of Medicine and Health Sciences, University of Papua New Guinea, Port Moresby, Papua New Guinea; Lihir Medical Center, International SOS-Newcrest Mining, Lihir Island, Papua New Guinea. Electronic address: oriol.mitja@isglobal.org.
Charmie GodornesDepartment of Medicine, University of Washington, Seattle, WA, USA.
Wendy HouineiDisease Control Branch, National Department of Health, Port Moresby, Papua New Guinea.
August KapaLihir Medical Center, International SOS-Newcrest Mining, Lihir Island, Papua New Guinea.
Raymond ParuLihir Medical Center, International SOS-Newcrest Mining, Lihir Island, Papua New Guinea.
Haina AbelLihir Medical Center, International SOS-Newcrest Mining, Lihir Island, Papua New Guinea.
Camila González-BeirasBarcelona Institute for Global Health, Hospital Clinic-University of Barcelona, Barcelona, Spain; Lisbon Institute of Hygiene and Tropical Medicine, Lisbon, Portugal.
Sibauk V BiebDisease Control Branch, National Department of Health, Port Moresby, Papua New Guinea.
James WangiOffice of the World Health Organization (WHO) Representative for Papua New Guinea, WHO, Port Moresby, Papua New Guinea.
Alyssa E BarryPopulation Health and Immunity Division, Walter and Eliza Hall Institute of Medical Research, Parkville, VIC, Australia; Department of Medical Biology, University of Melbourne, Parkville, VIC, Australia.
Sergi SanzBarcelona Institute for Global Health, Hospital Clinic-University of Barcelona, Barcelona, Spain; Biostatistics Unit, Department of Public Health, Faculty of Medicine, University of Barcelona, Barcelona, Spain.
Quique BassatBarcelona Institute for Global Health, Hospital Clinic-University of Barcelona, Barcelona, Spain; Institució Catalana de Recerca i Estudis Avançats, Barcelona, Spain; Centro de Investigação em Saúde de Manhiça, Maputo, Mozambique; Paediatric Infectious Diseases Unit, Paediatric Department, Hospital Sant Joan de Déu, Barcelona, Spain.
Sheila A LukehartDepartment of Medicine, University of Washington, Seattle, WA, USA; Department of Global Health, University of Washington, Seattle, WA, USA.
Papua New Guinea Institute of Medical Research · PGBarcelona Institute for Global Health · ESNational Department of Health · PGUniversity of Papua New Guinea · PGUniversity of Washington · USInstitució Catalana de Recerca i Estudis Avançats · ESThe University of Melbourne · AU

Funding

TREPONEMA PALLIDUM PATHOGENESIS ASSOCIATED MOLECULESR01AI042143 · NIAID · UNIVERSITY OF WASHINGTON · PI LUKEHART, SHEILA A. · 1998 to 2015
$5.4M
NIAID NIH HHS R01 AI042143World Health Organization 001
6 · The paper itself

Abstract

backgroundYaws is a substantial cause of chronic disfiguring ulcers in children in at least 14 countries in the tropics. WHO's newly adopted strategy for yaws eradication uses a single round of mass azithromycin treatment followed by targeted treatment programmes, and data from pilot studies have shown a short-term significant reduction of yaws. We assessed the long-term efficacy of the WHO strategy for yaws eradication.

methodsBetween April 15, 2013, and Oct 24, 2016, we did a longitudinal study on a Papua New Guinea island (Lihir; 16 092 population) in which yaws was endemic. In the initial study, the participants were followed for 12 months; in this extended follow-up study, clinical, serological, and PCR surveys were continued every 6 months for 42 months. We used genotyping and travel history to identify importation events. Active yaws confirmed by PCR specific for Treponema pallidum was the primary outcome indicator. The study is registered with ClinicalTrials.gov, number NCT01955252.

findingsMass azithromycin treatment (coverage rate of 84%) followed by targeted treatment programmes reduced the prevalence of active yaws from 1·8% to a minimum of 0·1% at 18 months (difference from baseline -1·7%, 95% CI, -1·9 to -1·4; p<0·0001), but the infection began to re-emerge after 24 months with a significant increase to 0·4% at 42 months (difference from 18 months 0·3%, 95% CI 0·1 to 0·4; p<0·0001). At each timepoint after baseline, more than 70% of the total community burden of yaws was found in individuals who had not had the mass treatment or as new infections in non-travelling residents. At months 36 and 42, five cases of active yaws, all from the same village, showed clinical failure following azithromycin treatment, with PCR-detected mutations in the 23S ribosomal RNA genes conferring resistance to azithromycin. A sustained decrease in the prevalence of high-titre latent yaws from 13·7% to <1·5% in asymptomatic children aged 1-5 years old and of genetic diversity of yaws strains from 0·139 to less than 0·046 between months 24 and 42 indicated a reduction in transmission of infection.

interpretationThe implementation of the WHO strategy did not, in the long-term, achieve elimination in a high-endemic community mainly due to the individuals who were absent at the time of mass treatment in whom yaws reactivated; repeated mass treatment might be necessary to eliminate yaws. To our knowledge, this is the first report of the emergence of azithromycin-resistant T p pertenue and spread within one village. Communities' surveillance should be strengthened to detect any possible treatment failure and biological markers of resistance.

fundingISDIN laboratories, Newcrest Mining Limited, and US Public Health Service National Institutes of Health.

Indexed as

Mass Drug AdministrationAdolescentAnti-Bacterial AgentsAzithromycinChildChild, PreschoolCommunicable Diseases, EmergingDisease EradicationDrug Resistance, BacterialFemaleGenetic VariationHumansInfantLongitudinal StudiesMalePapua New GuineaAnti-Bacterial AgentsAzithromycinRNA, Ribosomal, 23S

Identifiers

PMID29428183
PMCPMC5920722
OpenAlexW2785636783

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.